= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Tiphaine

MSACL 2018 EU Abstract

Topic: Small Molecules

Podium Presentation in the Ether on Thursday at 11:20 (Chair: Christiane Auray-Blais)

Quantification and Library Identification of 248 Compounds Commonly Detected in Systematic Toxicology Analysis Using an Automated Extraction Coupled to LC-MS/MS

Robin Tiphaine (Presenter)
CHU of Limoges

Presenter Bio(s): Tiphaine Robin obtained a State Doctorate of Pharmacy in 2017 (University of Limoges, France). She is currently PhD student in analytical chemistry. The main objective of her thesis is to develop innovative LC-MS screening procedures for applications in clinical and forensic toxicology. These works are under the supervision of both the Department of Pharmacology and Toxicology of the Limoges University Hospital (Pr Franck Saint-Marcoux and Dr Souleiman El Balkhi) and Shimadzu Corporation (Stephane Moreau, Shimadzu France, Marne-la-Vallée, France; Alban Huteau, Shimadzu France, Marne-la-Vallée, France). The Mass Spectrometry Business Unit (Overseas) of Shimadzu Corporation, with Neil Loftus and Alan Barnes, is also greatly involved in these developments.

Authors: Tiphaine Robin1; Alan Barnes2; Neil Loftus2; Sylvain Dulaurent1, Pierre Marquet1; Souleiman El Balkhi1, Franck Saint-Marcoux1;
1 - CHU de Limoges, Limoges, France; 2 -– Shimadzu Corporation, Manchester, UK


We report a fully automated extraction method carried out by a programable liquid handler directly coupled to an LC-MS/MS system for the identification and quantification of 248 compounds of interest. The acquisition was performed in positive and negative ionization mode with up to 15 MRM transitions per compound (MRM Spectrum mode). The method was validated according to the requirements of ISO 15189. A robustness study performed in 16 compounds demonstrated that samples could be quantified using a calibration curve dating up to one month.

Financial Disclosure

GrantsyesShimadzu corporation
Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: